Jeffrey Chodakewitz - 11 Jun 2025 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Reporting relationship: Director
Issuer ticker: ACET
Reported as of: 11 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2025, 16:08:41 UTC
Prior SEC filing: 23 Aug 2024
Next SEC filing: 20 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Nick Harvey, Attorney-in-Fact

Key filing fact

Jeffrey Chodakewitz filed Form 4 for Adicet Bio, Inc. (ACET) on 13 Jun 2025.

Key facts

This page summarizes Jeffrey Chodakewitz's Form 4 filing for Adicet Bio, Inc. (ACET).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2025, 16:08.

Change

Previous filing in this sequence was filed on 23 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001610876 Primary reporting owner

Chodakewitz Jeffrey

Relationship: Director
Address: C/O ADICET BIO, INC., 131 DARTMOUTH STREET, FLOOR 3, BOSTON
Signature: /s/ Nick Harvey, Attorney-in-Fact
Signature date: 13 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACET transaction

Common Stock

Award

Transaction value: $0
Shares: +5,900
Change %: +50%
Price: $0.000000
Shares after: 17,700
Date: 11 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACET transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +26,400
Change %
Price: $0.000000
Shares after: 26,400
Date: 11 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,400
Exercise price: $0.7800
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

Footnote F2

These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.